A proof-of-concept clinical trial of WP-1220 for the treatment of cutaneous T-cell lymphoma (CTCL)
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2018
At a glance
- Drugs WP 1220 (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Proof of concept; Therapeutic Use
- 09 Aug 2018 According to a Moleculin Biotech media release, company announced it has submitted a request to Polish authorities for clinical trial authorization (CTA) for its STAT3 inhibitor, WP1220, for the treatment of Cutaneous T-Cell Lymphoma (CTCL).
- 24 Oct 2017 According to a Moleculin Biotech media release, the company hope to be enrolling patients near year-end.
- 14 Sep 2017 New trial record